In preclinical models, anti-PD-1 therapy significantly suppressed the growth of murine melanoma, resulting in the proliferative burst of Tpex and increased the number of terminally exhausted CD8+ T cells with superior cytotoxicity (Table 1) (5). The gene discussed is PDCD1; the disease is melanoma.